Diligence memo · auto-generated · as of July 2, 2026

Tetra Bio-Pharma Inc.

Tetra Bio-Pharma Inc. looks fair against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Tetra Bio-Pharma Inc. operates in Pharmaceuticals, based in ORLEANS, ONTARIO.

Sub-sector tags: pharma.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Tetra Bio-Pharma Inc. has raised $371K in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).

Largest single filing: $371K on 2020-05-22.

Most recent recorded round closed around 2020-05-22.

Valuation (modeled)modeled

Provath models Tetra Bio-Pharma Inc. at approximately $18M (range $208K–$199M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 1.31× the median modeled value of Pre-Seed Pharmaceuticals companies in 2019–2021 (46 peers) — value vs value, same stage and era. Within the normal band (131% of peer median) for its niche.

Financing rhythm & timingmixed

Last raise 6.1 yr ago; this sector typically re-raises about every 13 months.

Only one round on record and long silent — often defunct, acquired, or gone quiet.

Comparablesmixed

Capital scale ranks ahead of 9% of Pharmaceuticals peers (1613 compared).

Modeled value ranks above 25% of those peers.

Closest niche peers: Elion Oncology, Inc., Cyclone Therapeutics, Inc., Sonnet Biotherapeutics, Inc., Fastball Capital Group, Llc, TamRx, LLC.

Peoplefiled

5 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.